High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection

References

• Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48(1):308–321. doi:10.1002/hep.22310
   PubMed Web of Science ®Google Scholar
• Sripa B, Kaewkes S, Sithithaworn P, et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007;4(7):e201. doi:10.1371/journal.pmed.0040201
   PubMed Web of Science ®Google Scholar
• Yongvanit P, Pinlaor S, Bartsch H. Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. Parasitol Int. 2012;61(1):130–135. doi:10.1016/j.parint.2011.06.011
   PubMed Web of Science ®Google Scholar
• Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y. Genomic and transcriptional alterations of cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014;21(6):380–387. doi:10.1002/jhbp.67
   PubMed Web of Science ®Google Scholar
• Titapun A, Techasen A, Sa-Ngiamwibool P, et al. Serum IgG as a marker for opisthorchis viverrini-associated cholangiocarcinoma correlated with HER2 overexpression. Int J Gen Med. 2020;13:1271–1283. doi:10.2147/IJGM.S282519
   PubMed Web of Science ®Google Scholar
• Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721–8743. doi:10.7150/thno.41648
   PubMed Web of Science ®Google Scholar
• Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45. doi:10.1038/nrm1004
   PubMed Web of Science ®Google Scholar
• Jakob M, Sharaf K, Schirmer M, et al. Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC. Strahlenther Onkol. 2021;197(3):231–245. doi:10.1007/s00066-020-01653-5
   PubMed Web of Science ®Google Scholar
• Siddiqui Z, Srivastava AN, Sankhwar SN, et al. Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis. Br J Biomed Sci. 2020;77(2):69–75. doi:10.1080/09674845.2019.1692761
   PubMed Web of Science ®Google Scholar
• Papadaki C, Manolakou S, Lagoudaki E, et al. Correlation of PKM2 and CD44 protein expression with poor prognosis in platinum-treated epithelial ovarian cancer: a Retrospective Study. Cancers (Basel). 2020;12(4):1013. doi:10.3390/cancers12041013
   PubMed Web of Science ®Google Scholar
• Zhou J, Du Y, Lu Y, et al. CD44 expression predicts prognosis of ovarian cancer patients through promoting epithelial-mesenchymal transition (EMT) by regulating snail, ZEB1, and Caveolin-1. Front Oncol. 2019;9:802. doi:10.3389/fonc.2019.00802
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Song Y, et al. CD44(+)/CD24(-) phenotype predicts a poor prognosis in triple-negative breast cancer. Oncol Lett. 2017;14(5):5890–5898. doi:10.3892/ol.2017.6959
   PubMed Web of Science ®Google Scholar
• Thanee M, Loilome W, Techasen A, et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment. Cancer Sci. 2016;107(7):991–1000. doi:10.1111/cas.12967
   PubMed Web of Science ®Google Scholar
• Morine Y, Imura S, Ikemoto T, Iwahashi S, Saito YU, Shimada M. CD44 expression is a prognostic factor in patients with intrahepatic cholangiocarcinoma after surgical resection. Anticancer Res. 2017;37(10):5701–5705. doi:10.21873/anticanres.12007
   PubMed Web of Science ®Google Scholar
• Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015;106(7):803–811. doi:10.1111/cas.12691
   PubMed Web of Science ®Google Scholar
• Ishiwata T, Matsuda Y, Naito Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol. 2011;17(4):409–418. doi:10.3748/wjg.v17.i4.409
   PubMed Web of Science ®Google Scholar
• Titapun A, Pugkhem A, Luvira V, et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World J Gastrointest Oncol. 2015;7(12):503–512. doi:10.4251/wjgo.v7.i12.503
   PubMed Web of Science ®Google Scholar
• Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–140. doi:10.1097/SLA.0b013e3182708b57
   PubMed Web of Science ®Google Scholar
• Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010;17(4):455–462. doi:10.1007/s00534-009-0208-1
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762. doi:10.1097/01.sla.0000251366.62632.d3
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(15_suppl):4006. doi:10.1200/JCO.2017.35.15_suppl.4006
   Web of Science ®Google Scholar
• Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021:1–8.
   Web of Science ®Google Scholar
• Jariwala AR, Oliveira LM, Diemert DJ, et al. Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines. 2010;9(10):1219–1230. doi:10.1586/erv.10.107
   PubMed Web of Science ®Google Scholar
• Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med. 2000;19(4):441–452. doi:10.1002/(SICI)1097-0258(20000229)19:4<441::AID-SIM349>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.
   PubMed Web of Science ®Google Scholar
• Itoh M, Pairojkul C, Thamawit W, et al. Association of antibodies to Opisthorchis viverrini with hepatobiliary disease in northeastern Thailand. Am J Trop Med Hyg. 1994;51(4):424–429. doi:10.4269/ajtmh.1994.51.424
   PubMed Web of Science ®Google Scholar
• Upatham ES, Viyanant V, Kurathong S, et al. Relationship between prevalence and intensity of Opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east Thailand. Bull World Health Organ. 1984;62(3):451–461.
   PubMed Web of Science ®Google Scholar
• Sithithaworn P, Andrews RH, Van De N, et al. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol Int. 2012;61(1):10–16. doi:10.1016/j.parint.2011.08.014
   PubMed Web of Science ®Google Scholar
• Sornlorm K, Loahasiriwong W, Sithithaworn P, Thinkhamrop W. Influence of geographic, knowledge and behavioral factors on opisthorchis viverrini infection in the Northeast of Thailand. Asian Pac J Trop Med. 2019;12(11):499–506. doi:10.4103/1995-7645.271289
   Web of Science ®Google Scholar
• Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17(4):449–454. doi:10.1007/s00534-009-0209-0
   PubMed Web of Science ®Google Scholar
• Luvira V, Nilprapha K, Bhudhisawasdi V, Pugkhem A, Chamadol N, Kamsa-ard S. Cholangiocarcinoma patient outcome in Northeastern Thailand: single-Center Prospective Study. Asian Pac J Cancer Prev. 2016;17(1):401–406. doi:10.7314/APJCP.2016.17.1.401
   PubMedGoogle Scholar
• Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci. 2010;17(4):476–489. doi:10.1007/s00534-009-0204-5
   PubMed Web of Science ®Google Scholar
• Unno M, Katayose Y, Rikiyama T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17(4):463–469. doi:10.1007/s00534-009-0206-3
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20. doi:10.1186/s12929-018-0426-4
   PubMed Web of Science ®Google Scholar
• Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology. 1998;27(4):974–982. doi:10.1002/hep.510270412
   PubMed Web of Science ®Google Scholar
• Padthaisong S, Thanee M, Namwat N, et al. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. J Transl Med. 2020;18(1):64. doi:10.1186/s12967-020-02243-w
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400. doi:10.1016/j.ccr.2011.01.038
   PubMed Web of Science ®Google Scholar
• Suwannakul N, Ma N, Thanan R, et al. Overexpression of CD44 variant 9: a novel cancer stem cell marker in human cholangiocarcinoma in relation to inflammation. Mediators Inflamm. 2018;2018:4867234. doi:10.1155/2018/4867234
   PubMed Web of Science ®Google Scholar
• Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients. J Gastroenterol Hepatol. 2013;28(12):1885–1891. doi:10.1111/jgh.12321
   PubMed Web of Science ®Google Scholar
• Rangarajan K, Simmons G, Manas D, Malik H, Hamady ZZ. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(4 Pt A):684–693. doi:10.1016/j.ejso.2019.11.499
   PubMed Web of Science ®Google Scholar
• Massa A, Varamo C, Vita F, et al. Evolution of the experimental models of cholangiocarcinoma. Cancers. 2020;12(8):2308. doi:10.3390/cancers12082308
   PubMed Web of Science ®Google Scholar
• Thanee M, Padthaisong S, Suksawat M, et al. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models. Cancer Metab. 2021;9(1):11. doi:10.1186/s40170-021-00249-6
   PubMed Web of Science ®Google Scholar